Adagene (ADAG) Other Non-Current Assets (2019 - 2026)
Adagene (ADAG) posted quarterly Other Non-Current Assets of $25.2 billion for Q4 2025, down 69.01% year-over-year from $81.4 billion in Q4 2024, and up 67369023.93% quarter-over-quarter from $37440.0 in Q2 2025.
Adagene (ADAG) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Other Non-Current Assets for 7 consecutive years, with $25.2 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets fell 69.01% year-over-year to $25.2 billion; the TTM figure through Dec 2025 stood at $25.2 billion (down 69.01% YoY), while the FY2025 annual figure was $25.2 billion, down 69.01% from the prior year.
- Other Non-Current Assets climbed to $25.2 billion in Q4 2025 per ADAG's latest filing, from $37440.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $109.6 billion in Q4 2022 and bottomed at $37440.0 in Q2 2025.
- Historically, Other Non-Current Assets has averaged $48.3 billion across 5 years, with a median of $49.0 billion in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 158169513.86% — and 2024, when it plunged 100.0%.
- Adagene's Other Non-Current Assets stood at $69275.0 in 2021, then soared by 158169513.86% to $109.6 billion in 2022, then declined by 22.53% to $84.9 billion in 2023, then decreased by 4.12% to $81.4 billion in 2024, then slumped by 69.01% to $25.2 billion in 2025.
- Business Quant data shows ADAG's Other Non-Current Assets at $25.2 billion in Q4 2025, $37440.0 in Q2 2025, and $81.4 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - | 59,794.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59,794.00 |
| Dec 31, 2025 | 25.22 Bn |
| Jun 30, 2025 | 37,440.00 |
| Dec 31, 2024 | 81.39 Bn |
| Jun 30, 2024 | 281,881.00 |
| Dec 31, 2023 | 84.89 Bn |
| Jun 30, 2023 | 108.92 Bn |
| Dec 31, 2022 | 109.57 Bn |
| Jun 30, 2022 | 72.80 Bn |
| Dec 31, 2021 | 69,275.00 |
| Jun 30, 2021 | 59,569.00 |
| Dec 31, 2020 | 3.10 Mn |
| Dec 31, 2019 | 87,227.00 |